Body

Department Body

Five outstanding biomedical researchers at the University of Colorado are part of the Boettcher Foundation’s 2022 class of Boettcher Investigators, recipients of grant funding through the Boettcher Foundation’s Webb-Waring Biomedical Research Awards Program.

CU’s 2022 Boettcher Investigators

CU’s new Boettcher Investigators and their research topics are:

University of Colorado Anschutz Medical Campus

Martin W. Breuss, Ph.D.; Elucidation of the features of germ cell mosaicism and its impact on human health.

Shanlee Davis, M.D., Ph.D.; Pathophysiology of cardiometabolic dysfunction in Klinefelter Syndrome.

Michael S. Leibowitz, M.D., Ph.D.; Altering the tumor microenvironment to increase epitope spreading and augment chimeric antigen receptor T cell therapy for metastatic osteosarcoma.

Andrew C. Smith, P.T., D.P.T., Ph.D.; Spinal cord lesion determinants of optimal responsiveness to spinal cord stimulation.

University of Colorado Boulder

Aaron T. Whiteley, Ph.D.; Novel mechanisms of STING signaling in disease.

The Boettcher Foundation Webb-Waring Biomedical Research Awards Program supports early career investigators whose research has a direct impact on human health. The biomedical research supported pursuant to this grant program will be designed to find ways to prevent disease and improve human health through basic and applied biomedical research. The intent of the program is to fund meritorious research that has the potential for new discoveries or advances a discovery to the proof of its potential value as an application to improve human health. This research will improve the understanding, treatment and prevention of human disease. Awardees will carry the prestigious title of Boettcher Investigator.

CU’s fifty-nine Boettcher Investigators have been awarded a total of $13,720,000 since the program was initiated in 2010. See all CU Boettcher Investigators.

ELIGIBILITY CRITERIA AND DEADLINES

Eligibility crteria and application deadlines for the 2023 Awards will be announced in late 2022.